[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive sleep dysfunction with dream enactment (REM behavior disorder), non-REM parasomnias, nocturnal stridor, daytime somnolence, gait instability, mild cognitive decline, normal CSF, and mild cerebellar atrophy on MRI. These findings align precisely with anti-IgLON5 disease, a tauopathy featuring severe sleep disorders, bulbar symptoms (stridor), gait issues, and cognitive decline, with often normal CSF and nonspecific MRI changes. The question asks for the most likely associated antibody in this syndrome. Main logical issue(s): none; the stem provides sufficient discriminating details to identify anti-IgLON5 as the unique best without contradictions or underspecification. Alternatives are inferior: Anti-Hu (A) links to paraneoplastic limbic encephalitis with seizures, not prominent sleep issues; Anti-Yo (B) causes cerebellar degeneration with ataxia, lacking sleep predominance; Anti-Ma2 (D) involves diencephalic/brainstem encephalitis with possible sleep changes but often hypothalamic features and abnormal CSF; Anti-NMDA (E) presents with psychiatric symptoms, dyskinesias, and CSF pleocytosis, not matching normal CSF or chronic progression. Main medical accuracy issue(s): none; consistent with current neurology guidelines on autoimmune encephalopathies, including IgLON5's tauopathy association and typical presentations. Minimal fix: none needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive sleep dysfunction with dream enactment (REM behavior disorder), non-REM parasomnias, nocturnal stridor, daytime somnolence, gait instability, mild cognitive decline, normal CSF, and mild cerebellar atrophy on MRI. These findings align precisely with anti-IgLON5 disease, a tauopathy featuring severe sleep disorders, bulbar symptoms (stridor), gait issues, and cognitive decline, with often normal CSF and nonspecific MRI changes. The question asks for the most likely associated antibody in this syndrome. Main logical issue(s): none; the stem provides sufficient discriminating details to identify anti-IgLON5 as the unique best without contradictions or underspecification. Alternatives are inferior: Anti-Hu (A) links to paraneoplastic limbic encephalitis with seizures, not prominent sleep issues; Anti-Yo (B) causes cerebellar degeneration with ataxia, lacking sleep predominance; Anti-Ma2 (D) involves diencephalic/brainstem encephalitis with possible sleep changes but often hypothalamic features and abnormal CSF; Anti-NMDA (E) presents with psychiatric symptoms, dyskinesias, and CSF pleocytosis, not matching normal CSF or chronic progression. Main medical accuracy issue(s): none; consistent with current neurology guidelines on autoimmune encephalopathies, including IgLON5's tauopathy association and typical presentations. Minimal fix: none needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Irregular vaginal bleeding 18 months post-term delivery, mildly elevated serum hCG (150 mIU/mL), 4 cm intrauterine mass on MRI, endometrial biopsy showing sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, IHC strongly positive for hPL but negative for hCG.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details to identify a single best diagnosis without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with current standards for gestational trophoblastic diseases, including PSTT characteristics (hPL positivity, low hCG, post-pregnancy presentation).\\nMinimal fix: No edit needed; item is already unambiguous and accurate.\\n\\nBest-answer defensibility:\\na) The question asks for the most likely gestational trophoblastic disease based on clinical, lab, imaging, and biopsy findings.\\nb) Key findings: Delayed presentation post-delivery, mild hCG elevation, intrauterine mass, intermediate trophoblasts with hPL+ / hCG- IHC, low mitotics.\\nc) Most likely: Placental site trophoblastic tumor (PSTT).\\nd) Keyed answer B fits: PSTT derives from intermediate trophoblasts, expresses hPL strongly, minimal hCG, presents months-years post-pregnancy with bleeding and mass; no major assumptions needed.\\ne) A: Choriocarcinoma - worse due to typically high hCG and hCG+ IHC.\\nC: Epithelioid trophoblastic tumor - incorrect as it arises from chorionic-type trophoblasts, often p63+, weaker hPL.\\nD: Persistent hydatidiform mole - lacks villous structures on biopsy.\\nE: Invasive mole - high hCG, villi present.\\n\\nLogical validity: V - Stem allows unique best option B, matching key.\\nMedical accuracy: Consistent with guidelines (e.g., FIGO); no inaccuracies or outdated info.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Irregular vaginal bleeding 18 months post-term delivery, mildly elevated serum hCG (150 mIU/mL), 4 cm intrauterine mass on MRI, endometrial biopsy showing sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, IHC strongly positive for hPL but negative for hCG.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details to identify a single best diagnosis without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with current standards for gestational trophoblastic diseases, including PSTT characteristics (hPL positivity, low hCG, post-pregnancy presentation).\nMinimal fix: No edit needed; item is already unambiguous and accurate.\n\nBest-answer defensibility:\na) The question asks for the most likely gestational trophoblastic disease based on clinical, lab, imaging, and biopsy findings.\nb) Key findings: Delayed presentation post-delivery, mild hCG elevation, intrauterine mass, intermediate trophoblasts with hPL+ / hCG- IHC, low mitotics.\nc) Most likely: Placental site trophoblastic tumor (PSTT).\nd) Keyed answer B fits: PSTT derives from intermediate trophoblasts, expresses hPL strongly, minimal hCG, presents months-years post-pregnancy with bleeding and mass; no major assumptions needed.\ne) A: Choriocarcinoma - worse due to typically high hCG and hCG+ IHC.\nC: Epithelioid trophoblastic tumor - incorrect as it arises from chorionic-type trophoblasts, often p63+, weaker hPL.\nD: Persistent hydatidiform mole - lacks villous structures on biopsy.\nE: Invasive mole - high hCG, villi present.\n\nLogical validity: V - Stem allows unique best option B, matching key.\nMedical accuracy: Consistent with guidelines (e.g., FIGO); no inaccuracies or outdated info.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 18-year-old with confirmed Danon disease (LAMP2 mutation), severe hypertrophic cardiomyopathy (septal thickness 28 mm), WPW with three accessory pathways, recurrent syncope, and pre-excited AF refractory to maximal medical therapy. These indicate progressive, life-threatening cardiomyopathy and arrhythmias typical of Danon disease, with high mortality risk warranting advanced intervention.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting D as the unique best next step given disease progression and therapy failure.\\nMain medical accuracy issue(s), if any: None; aligns with current understanding of Danon disease as a rapidly progressive lysosomal storage disorder causing HCM, multifocal accessory pathways, and poor response to ablation or antiarrhythmics. Guidelines emphasize early transplant evaluation due to high arrhythmic and heart failure mortality, with beta-blockers contraindicated in pre-excited AF and ablation often futile due to recurrence.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 18-year-old with confirmed Danon disease (LAMP2 mutation), severe hypertrophic cardiomyopathy (septal thickness 28 mm), WPW with three accessory pathways, recurrent syncope, and pre-excited AF refractory to maximal medical therapy. These indicate progressive, life-threatening cardiomyopathy and arrhythmias typical of Danon disease, with high mortality risk warranting advanced intervention.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting D as the unique best next step given disease progression and therapy failure.\nMain medical accuracy issue(s), if any: None; aligns with current understanding of Danon disease as a rapidly progressive lysosomal storage disorder causing HCM, multifocal accessory pathways, and poor response to ablation or antiarrhythmics. Guidelines emphasize early transplant evaluation due to high arrhythmic and heart failure mortality, with beta-blockers contraindicated in pre-excited AF and ablation often futile due to recurrence.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include 42-year-old with MS on natalizumab for 30 months, subacute cognitive decline over 3 weeks, JCV antibody index 2.8, new non-enhancing subcortical white matter lesions on MRI without mass effect, and positive CSF JCV PCR, collectively diagnostic for natalizumab-associated progressive multifocal leukoencephalopathy (PML). These drive a unique best answer of immediate plasma exchange (PLEX) to accelerate natalizumab clearance, enable immune reconstitution, and improve survival odds. No main logical issues; stem is coherent, supports single best option without contradictions or underspecification, and options are discriminable. Main medical accuracy issues: Item aligns with current guidelines (e.g., AAN, MS Society) emphasizing prompt natalizumab discontinuation and PLEX for PML; however, provided rationale slightly misstates PLEX as preventing IRIS (it actually precipitates manageable IRIS). Vignette and options are clinically realistic and board-relevant. Minimal fix: Revise rationale to clarify 'PLEX accelerates immune reconstitution, potentially causing IRIS which is then managed, improving survival' for precision, though item itself requires no edit.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include 42-year-old with MS on natalizumab for 30 months, subacute cognitive decline over 3 weeks, JCV antibody index 2.8, new non-enhancing subcortical white matter lesions on MRI without mass effect, and positive CSF JCV PCR, collectively diagnostic for natalizumab-associated progressive multifocal leukoencephalopathy (PML). These drive a unique best answer of immediate plasma exchange (PLEX) to accelerate natalizumab clearance, enable immune reconstitution, and improve survival odds. No main logical issues; stem is coherent, supports single best option without contradictions or underspecification, and options are discriminable. Main medical accuracy issues: Item aligns with current guidelines (e.g., AAN, MS Society) emphasizing prompt natalizumab discontinuation and PLEX for PML; however, provided rationale slightly misstates PLEX as preventing IRIS (it actually precipitates manageable IRIS). Vignette and options are clinically realistic and board-relevant. Minimal fix: Revise rationale to clarify 'PLEX accelerates immune reconstitution, potentially causing IRIS which is then managed, improving survival' for precision, though item itself requires no edit.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 5-year chronic urticarial rash refractory to H1/H2 antihistamines, recurrent fevers, debilitating bone pain, monoclonal IgM kappa on electrophoresis, and markedly elevated ESR/CRP—these collectively point to Schnitzler syndrome, an autoinflammatory disorder with IL-1β overproduction as the central mechanism. Main logical issue(s), if any: None; the vignette provides sufficient discriminating details to identify Schnitzler syndrome uniquely, allowing selection of IL-1 as the primary therapeutic target without contradictions or underspecification. Alternatives are plausibly incorrect: IL-6 (B) and TNF-alpha (D) may be secondarily elevated but not primary drivers; IL-17 (C) and IFN-gamma (E) are unrelated to pathogenesis. Main medical accuracy issue(s), if any: None; aligns with current understanding of Schnitzler syndrome as NLRP3 inflammasome-mediated, with IL-1 antagonism (e.g., anakinra) as first-line therapy per guidelines, while other cytokines are not central. The item's logic is precise and reflects board-relevant knowledge without inaccuracies or outdated elements. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 5-year chronic urticarial rash refractory to H1/H2 antihistamines, recurrent fevers, debilitating bone pain, monoclonal IgM kappa on electrophoresis, and markedly elevated ESR/CRP—these collectively point to Schnitzler syndrome, an autoinflammatory disorder with IL-1β overproduction as the central mechanism. Main logical issue(s), if any: None; the vignette provides sufficient discriminating details to identify Schnitzler syndrome uniquely, allowing selection of IL-1 as the primary therapeutic target without contradictions or underspecification. Alternatives are plausibly incorrect: IL-6 (B) and TNF-alpha (D) may be secondarily elevated but not primary drivers; IL-17 (C) and IFN-gamma (E) are unrelated to pathogenesis. Main medical accuracy issue(s), if any: None; aligns with current understanding of Schnitzler syndrome as NLRP3 inflammasome-mediated, with IL-1 antagonism (e.g., anakinra) as first-line therapy per guidelines, while other cytokines are not central. The item's logic is precise and reflects board-relevant knowledge without inaccuracies or outdated elements. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the treatment modality shown to halt neurologic progression in cerebrotendinous xanthomatosis (CTX). Key stem clues driving a unique best answer include the diagnosis of CTX with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, cerebellar ataxia, and markedly elevated serum cholestanol, which collectively point to cholestanol accumulation due to CYP27A1 deficiency. The most likely mechanism is reduced cholestanol synthesis via bile acid replacement. Keyed answer B (chenodeoxycholic acid supplementation) fits as it inhibits cholesterol 7α-hydroxylase, reduces cholestanol, and stabilizes neurologic function per standard guidelines. Alternatives: A (high-intensity statin therapy) is worse because statins primarily lower cholesterol but not CNS cholestanol effectively; C (weekly LDL apheresis) is incorrect as it's not standard for CTX and doesn't target neural accumulation; D (ezetimibe monotherapy) fails to address cholestanol synthesis; E (coenzyme Q10 supplementation) is irrelevant, used for mitochondrial disorders. No main logical issues, as the stem allows discrimination of a single best option without contradictions or underspecification. No main medical accuracy issues; the item aligns with current mainstream standards, including UpToDate and genetic disorder guidelines, where CDCA is first-line to prevent progression. Minimal fix: No edit required, but to enhance precision, add 'oral' to option B for clarity on administration.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the treatment modality shown to halt neurologic progression in cerebrotendinous xanthomatosis (CTX). Key stem clues driving a unique best answer include the diagnosis of CTX with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, cerebellar ataxia, and markedly elevated serum cholestanol, which collectively point to cholestanol accumulation due to CYP27A1 deficiency. The most likely mechanism is reduced cholestanol synthesis via bile acid replacement. Keyed answer B (chenodeoxycholic acid supplementation) fits as it inhibits cholesterol 7α-hydroxylase, reduces cholestanol, and stabilizes neurologic function per standard guidelines. Alternatives: A (high-intensity statin therapy) is worse because statins primarily lower cholesterol but not CNS cholestanol effectively; C (weekly LDL apheresis) is incorrect as it's not standard for CTX and doesn't target neural accumulation; D (ezetimibe monotherapy) fails to address cholestanol synthesis; E (coenzyme Q10 supplementation) is irrelevant, used for mitochondrial disorders. No main logical issues, as the stem allows discrimination of a single best option without contradictions or underspecification. No main medical accuracy issues; the item aligns with current mainstream standards, including UpToDate and genetic disorder guidelines, where CDCA is first-line to prevent progression. Minimal fix: No edit required, but to enhance precision, add 'oral' to option B for clarity on administration.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include cyclic right pelvic pain worsening with menses, normal menstrual bleeding indicating a patent left uterine horn, didelphic uterus with 5 cm right hematocolpos suggesting obstruction, and absent right kidney pointing to ipsilateral renal anomaly. These precisely match OHVIRA syndrome (Obstructed Hemivagina and Ipsilateral Renal Anomaly), making B the single best answer. No logical issues: the vignette is internally consistent, supports exactly one defensible option without contradictions or underspecification, and the key aligns perfectly. Alternatives are inferior—A (MRKH) involves uterine agenesis, not a didelphic uterus; C (CAIS) affects 46,XY individuals without a uterus; D (transverse vaginal septum) and E (imperforate hymen) typically present with normal uterus and bilateral kidneys, lacking renal agenesis and didelphic features. No medical accuracy issues: the item's logic aligns with current gynecologic and urologic standards, accurately associating OHVIRA with Müllerian anomalies and renal agenesis per mainstream guidelines. Minimal fix: No edit required; item is already unambiguous and accurate. The clinical problem asks for the congenital anomaly explaining unilateral hematocolpos in a didelphic uterus with ipsilateral renal agenesis. Discriminating findings: positive (right-sided cyclic pain, hematocolpos, absent kidney); negative (normal menses, normal left horn). Implied diagnosis: OHVIRA. Keyed answer fits without assumptions.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include cyclic right pelvic pain worsening with menses, normal menstrual bleeding indicating a patent left uterine horn, didelphic uterus with 5 cm right hematocolpos suggesting obstruction, and absent right kidney pointing to ipsilateral renal anomaly. These precisely match OHVIRA syndrome (Obstructed Hemivagina and Ipsilateral Renal Anomaly), making B the single best answer. No logical issues: the vignette is internally consistent, supports exactly one defensible option without contradictions or underspecification, and the key aligns perfectly. Alternatives are inferior—A (MRKH) involves uterine agenesis, not a didelphic uterus; C (CAIS) affects 46,XY individuals without a uterus; D (transverse vaginal septum) and E (imperforate hymen) typically present with normal uterus and bilateral kidneys, lacking renal agenesis and didelphic features. No medical accuracy issues: the item's logic aligns with current gynecologic and urologic standards, accurately associating OHVIRA with Müllerian anomalies and renal agenesis per mainstream guidelines. Minimal fix: No edit required; item is already unambiguous and accurate. The clinical problem asks for the congenital anomaly explaining unilateral hematocolpos in a didelphic uterus with ipsilateral renal agenesis. Discriminating findings: positive (right-sided cyclic pain, hematocolpos, absent kidney); negative (normal menses, normal left horn). Implied diagnosis: OHVIRA. Keyed answer fits without assumptions.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Acute hemolysis (dark urine, LDH 2800 U/L, plasma free hemoglobin 80 mg/dL), fatigue, dizziness, increased device power consumption with intermittent spikes, and TTE suggesting inflow cannula obstruction collectively indicate HeartMate 3 LVAD pump thrombosis. These findings support targeted thrombolysis as immediate management, aligning with D (intrapump alteplase 10 mg via percutaneous catheter) due to its direct delivery minimizing systemic risks while addressing established thrombosis.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details without contradictions, allowing a single best answer (D) over alternatives: A (increasing INR is preventive, not acute); B (heparin enhances anticoagulation but doesn't lyse clot); C (intraventricular alteplase risks hemorrhage without targeting pump); E (surgery is invasive, reserved for failures).\\nMain medical accuracy issue(s), if any: None; consistent with current guidelines for LVAD thrombosis management, where low-dose intrapump thrombolysis shows high efficacy and safety for HeartMate 3, avoiding systemic thrombolysis complications. Implied logic aligns with standard care, including reserving surgery for hemodynamic instability.\\nMinimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Acute hemolysis (dark urine, LDH 2800 U/L, plasma free hemoglobin 80 mg/dL), fatigue, dizziness, increased device power consumption with intermittent spikes, and TTE suggesting inflow cannula obstruction collectively indicate HeartMate 3 LVAD pump thrombosis. These findings support targeted thrombolysis as immediate management, aligning with D (intrapump alteplase 10 mg via percutaneous catheter) due to its direct delivery minimizing systemic risks while addressing established thrombosis.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details without contradictions, allowing a single best answer (D) over alternatives: A (increasing INR is preventive, not acute); B (heparin enhances anticoagulation but doesn't lyse clot); C (intraventricular alteplase risks hemorrhage without targeting pump); E (surgery is invasive, reserved for failures).\nMain medical accuracy issue(s), if any: None; consistent with current guidelines for LVAD thrombosis management, where low-dose intrapump thrombolysis shows high efficacy and safety for HeartMate 3, avoiding systemic thrombolysis complications. Implied logic aligns with standard care, including reserving surgery for hemodynamic instability.\nMinimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Immunocompetent gardener with soil exposure, subacute (3 weeks) headaches, focal seizures, hemiparesis; MRI multiple ring-enhancing lesions with edema; CSF lymphocytic pleocytosis (120 cells/μL), negative bacterial/fungal/mycobacterial cultures. These point to granulomatous amebic encephalitis from Balamuthia mandrillaris, a free-living amoeba associated with soil in healthy hosts, distinguishing from Acanthamoeba (often immunocompromised or contact lens-related), fungal infections (negative cultures, voriconazole option), bacterial abscess (negative cultures, acute, neutrophilic CSF), or viral like CMV (immunocompromised, antiviral option). Keyed B (albendazole + miltefosine) fits CDC-recommended therapy for Balamuthia. Main logical issue(s), if any: None; stem provides sufficient discriminating clues (soil exposure, immunocompetent, subacute course, CSF profile) to identify unique best without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current understanding of Balamuthia presentation and empiric treatment per CDC guidelines, though rare and often confirmed by PCR/biopsy in practice. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Immunocompetent gardener with soil exposure, subacute (3 weeks) headaches, focal seizures, hemiparesis; MRI multiple ring-enhancing lesions with edema; CSF lymphocytic pleocytosis (120 cells/μL), negative bacterial/fungal/mycobacterial cultures. These point to granulomatous amebic encephalitis from Balamuthia mandrillaris, a free-living amoeba associated with soil in healthy hosts, distinguishing from Acanthamoeba (often immunocompromised or contact lens-related), fungal infections (negative cultures, voriconazole option), bacterial abscess (negative cultures, acute, neutrophilic CSF), or viral like CMV (immunocompromised, antiviral option). Keyed B (albendazole + miltefosine) fits CDC-recommended therapy for Balamuthia. Main logical issue(s), if any: None; stem provides sufficient discriminating clues (soil exposure, immunocompetent, subacute course, CSF profile) to identify unique best without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current understanding of Balamuthia presentation and empiric treatment per CDC guidelines, though rare and often confirmed by PCR/biopsy in practice. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent fevers, livedo racemosa, recurrent lacunar strokes, vasculitic neuropathy, low IgM, elevated IgA, negative ANCA, and confirmed biallelic ADA2 mutations, pointing to Deficiency of Adenosine Deaminase 2 (DADA2), a monogenic vasculitis with TNF-alpha overproduction. These findings support etanercept as the most effective biologic therapy due to its TNF-alpha inhibition, inducing remission. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., genetic confirmation, specific clinical features) to identify a single best answer without contradictions or underspecification. Alternatives are inferior: A) High-dose glucocorticoids are non-biologic and less effective long-term; B) Intravenous cyclophosphamide is immunosuppressive but not targeted to TNF pathway; D) Anakinra (IL-1 inhibitor) shows variable response in DADA2; E) Rituximab is ineffective as DADA2 is not B-cell mediated. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., EULAR recommendations) emphasizing anti-TNF agents like etanercept as first-line for DADA2 vasculitis, with accurate pathophysiology (macrophage defects leading to TNF overproduction). Minimal fix: none needed; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent fevers, livedo racemosa, recurrent lacunar strokes, vasculitic neuropathy, low IgM, elevated IgA, negative ANCA, and confirmed biallelic ADA2 mutations, pointing to Deficiency of Adenosine Deaminase 2 (DADA2), a monogenic vasculitis with TNF-alpha overproduction. These findings support etanercept as the most effective biologic therapy due to its TNF-alpha inhibition, inducing remission. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., genetic confirmation, specific clinical features) to identify a single best answer without contradictions or underspecification. Alternatives are inferior: A) High-dose glucocorticoids are non-biologic and less effective long-term; B) Intravenous cyclophosphamide is immunosuppressive but not targeted to TNF pathway; D) Anakinra (IL-1 inhibitor) shows variable response in DADA2; E) Rituximab is ineffective as DADA2 is not B-cell mediated. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., EULAR recommendations) emphasizing anti-TNF agents like etanercept as first-line for DADA2 vasculitis, with accurate pathophysiology (macrophage defects leading to TNF overproduction). Minimal fix: none needed; item is unambiguous and accurate as is.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]